v3.25.4
Agreements with Ligand Pharmaceuticals Incorporated - Additional Information (Detail) - USD ($)
1 Months Ended 12 Months Ended
May 31, 2014
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
License agreement entered date   2014-05    
Common stock issued value as part of partial consideration of agreement   $ 73,948,000 $ 643,797,000 $ 271,882,000
Ligand [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
One time nonrefundable mile stone payments maximum payable amount   1,540,000,000    
Legal costs   $ 0    
Sale and transfer of price equals to percentage of cost of goods   125.00%    
Ligand [Member] | Management Rights Letter [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Date agreement might terminate Mar. 28, 2023      
Ligand [Member] | Minimum [Member] | Management Rights Letter [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Percentage of voting interest beneficiary owned 7.50%      
IPO [Member] | Ligand [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Common stock issued as part of partial consideration of agreement   3,655,964    
Common stock issued value as part of partial consideration of agreement   $ 29,200,000